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Abstract
Purpose The development of multidrug resistance
(MDR) is one of the major limitations in the treatment of
cancer. Induction of P-glycoprotein (Pgp) has been
regarded as one of the main mechanisms underlying anti-
cancer drug-induced MDR. Since the induction of Pgp is
(in part) regulated by the pregnane X receptor (PXR), the
ability of several widely used anticancer drugs to activate
PXR-mediated Pgp induction was investigated.
Methods A Pgp-reporter gene assay was employed to
determine the ability of a panel of widely used anticancer
drugs to induce Pgp. To further assess whether PXR could
be involved in the induction of Pgp by anticancer drugs,
Pgp protein expression after treatment with the anticancer
drugs was determined in both wild-type and PXR-knocked
down LS180 cells. Furthermore, the eVect of the anticancer
drugs on the intracellular accumulation of the Pgp-probes
rhodamine 123 and doxorubicin was determined.
Results Our study showed that vincristine, tamoxifen,
vinblastine, docetaxel, cyclophosphamide, Xutamide, ifosfa-
mide and paclitaxel activate PXR-mediated Pgp induction,
and were additionally shown to aVect the intracellular accu-
mulation of the Pgp probe rhodamine 123. Moreover, PXR
activation was also shown to reduce the cytotoxic activity
of the Pgp substrate doxorubicin in colon cancer cells.
Conclusion Our results indicate that several anticancer
drugs can activate PXR-mediated induction of Pgp and
aVect the accumulation of Pgp substrates.
Keywords PXR · Induction · P-glycoprotein · Multidrug 
resistance · Anticancer drugs
Abbreviations
ABC ATP-binding cassette
ATP Adenosine triphosphate
DMSO Dimethylsulfoxide
HBSS Hank’s Balanced Salt Solution
HRP Horse radish peroxidise
MDR Multidrug resistance
NR Nuclear receptor
PBS phosphate buVer saline
Pgp P-glycoprotein
PXR Pregnane X receptor
Introduction
A major drawback in the successful treatment of advanced
malignancies is the development of multidrug resistance
(MDR). One of the main causes by which cancer cells
acquire the multidrug resistant phenotype in response to
chemotherapy is the induction of ATP-binding cassette
(ABC) drug eZux transporter proteins. An important
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mediator of MDR that has been associated with poor
treatment response in various malignancies is the ABC-family
member P-glycoprotein (Pgp; ABCB1; MDR1) [1–3]. Pgp
is a transmembrane protein that protects the cell from xeno-
biotic stress by facilitating the extrusion of a broad spec-
trum of substrates, including anticancer drugs such as the
anthracyclines, epipodophyllotoxins, Vinca alkaloids and
taxanes. As a consequence, induction of Pgp aVects the
eYcacy of these agents by decreasing their intracellular
accumulation in cancer cells.
The pregnane X receptor (PXR; NR1I2) has been iden-
tiWed as a major regulator of Pgp induction [4], and, apart
from expression in the liver and small intestines, has been
shown to be expressed in several cancerous tissues such
as breast, colon, bone, prostate and endometrial cancers
[5–9]. PXR is a very promiscuous receptor that is acti-
vated by a wide variety of structurally unrelated ligands
including rifampicin, hyperforin and the anticancer drug
paclitaxel. Due to the promiscuity of PXR, possibly other
widely used anticancer drugs could also activate PXR-
mediated Pgp induction, and as a consequence induce
MDR in cancer cells.
In the current study, a panel of widely used anticancer
drugs was evaluated for their ability to activate PXR-
mediated Pgp induction in the colon adenocarcinoma-
derived cell line LS180. In addition, the eVect of PXR
activation on the intracellular accumulation of Pgp sub-
strates was determined. Our results demonstrate that several
widely used anticancer drugs can activate PXR-mediated
induction of Pgp and as a consequence decrease the
intracellular accumulation of Pgp substrates. In addition,
evidence is presented that the cytotoxic activity of doxoru-
bicin is reduced when cells are pretreated with the PXR
activator rifampicin.
Materials and methods
Materials
All cell culture media and supplements were purchased
from Invitrogen (Breda, The Netherlands). Carboplatin,
ifosfamide, tamoxifen citrate and etoposide were obtained
from Axxora (San Diego, CA, USA). Zosuquidar (LY335979)
was obtained through Kanisa Pharmaceuticals Inc. (Irvine,
CA, USA). All other chemicals were purchased from
Sigma–Aldrich (Zwijndrecht, The Netherlands).
Plasmids
The pGL3-MDR1 (p-10224) luciferase reporter construct
was generously provided by Dr. Oliver Burk (Institute of
Clinical Pharmacology, Eberhard-Karls University, Tübingen,
Germany). The pCDG-hPXR expression vector was
generously provided by Dr. Ron Evans (Salk institute for
biological studies, La Jolla, CA, USA). The pRL-TK con-
trol plasmid was obtained from Promega (Madison, WI,
USA). Plasmids were checked by enzyme restriction and
agarose gel electrophoresis and puriWed using Promega’s
Pureyield Midi-prep (Madison, WI, USA) according to the
instructions of the manufacturer.
Cell culture
The human colon adenocarcinoma-derived cell line
LS180 was purchased from the ATCC (Manassas, VA,
USA). The cell-line was maintained in Roswell Park
Memorial Institute (RPMI) 1640 medium (with 25 mM
HEPES and L-glutamine, supplemented with 10% (v/v)
heat-inactivated fetal bovine serum, 100 U/ml penicillin
and 100 g/ml streptomycin), at 37°C under a humidiWed
atmosphere of 5% CO2.
Cell viability
Cell viability was after 48 h, and the anticancer drug treat-
ment was assessed with a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT)-assay.
Pgp reporter gene assay
The Pgp reporter gene assay was performed in a similar
manner as described previously [10]. In brief, LS180
cells were transfected with a pCDG-hPXR expression
vector, a pGL3-MDR1 luciferase reporter construct, and
a pRL-TK control plasmid for 24 h. After transfection,
the transiently transfected LS180 cells were treated with
the highest non-toxic concentration of each anticancer
drug. After 48 h incubation, the reporter activity was
determined.
Cell treatment
LS180 cells were plated at a density of 5 £ 104 cells/well in
96 well plates (Pgp protein level determination) or 1 £ 105
cells/well in 1 ml RMPI in 24 well plates (Pgp transport
activity). After reaching 80–90% conXuency, medium was
replaced with medium containing the diVerent anticancer
drugs: carboplatin (10 M), cyclophosphamide (100 M),
ifosfamide (100 M), docetaxel (10 M), paclitaxel
(10 M), Xutamide (10 M) and tamoxifen (10 M). Rif-
ampicin (10 M) was used as a positive control and DMSO
(0.1%) as a negative control. The cells were treated for 48 h
with the drugs and the controls. At the end of each treat-
ment, the cells were processed for immunoblotting or rho-
damine 123-based Pgp activity assays.Cancer Chemother Pharmacol (2010) 66:765–771 767
123
RNA interference of PXR
The siRNA sequence targeting human PXR (sense: cguuu-
guucgcuuccugagtt; antisense: cucaggaagcgaacaaacgtg) and
the negative control, which consisted of a non-complementary
sequence, were purchased from Ambion (Austin, TX,
USA). LS180 cells were reversely transfected 48 h prior to
the Pgp induction experiment with 50 nM siRNA PXR or
50 nM negative control siRNA using Lipofectamine RNAi
Max (Invitrogen, Breda, The Netherlands). Subsequently,
PXR knockdown and control LS180 cells were treated with
diVerent anticancer drugs for 48 h.
Immunoblot analysis
After 48 h of culture, cells were washed with phosphate-
buVered saline (PBS), and lysed in 1 ml/well MilliQ water
that contained protease inhibitors (Roche, Basal, Switzerland).
The lysate was centrifuged (5,000 rpm, 5 min, 4°C), and
the remaining pellet was resuspended in 100 L RIPA
buVer. The lysate was centrifuged (10,000 rpm, 5 min, 4°C)
and the supernatant was transferred to a new collection
tube. Protein concentrations were determined by a Pierce
BCA protein assay (Pierce, Rockford, IL, USA). Ten
micrograms of total protein was separated by SDS–
polyacrylamide gel electrophoresis using NuPage novex
4–12% bis–tris gradient gels (Invitrogen, Breda, The
Netherlands). Proteins were electroblotted onto Immobilon
P membranes (Millipore, Bedford, MA, USA). After block-
ing (1 h at RT) in 3% BSA in tris-buVered saline containing
0.1% Tween-20, the membranes were incubated overnight
at 4°C with a murine monoclonal anti-Pgp primary anti-
body (C219, 1:500; Abcam, Cambridge, UK) followed by
incubation with a goat anti-mouse IgG coupled to horse
radish peroxidase (HRP) secondary antibody (1:1,000;
ImmunoPure Peroxidase Conjugated Goat anti-Mouse IgG
(H + L); Pierce, Rockford, IL, USA). -actin (1:10,000;
AC-15; Abcam, Cambridge, UK) was used as a loading
control. The proteins were visualized by a chemilumines-
cence-based detection reagent (SuperSignal West Femto;
Pierce, Rockford, IL, USA), and the intensities of the Pgp
bands were determined on a Gel Doc XRS Imaging system
with Quantity One analysis software (Bio-Rad, Hercules,
CA, USA). The ratio of the Pgp signal and the -actin signal
were indicative for Pgp protein expression.
Rhodamine 123 accumulation assay
The eZux activity of Pgp was determined by measuring the
accumulation of the Xuorescent Pgp probe rhodamine 123
as described by Collett et al. [ 11]. In brief, LS180 cells
were pretreated with the anticancer drugs as described
earlier. After 48 h, the cells were washed with Hank’s
Balanced Salt Solution (HBSS) and incubated at 37°C for
1 h with rhodamine 123 (10 M) in the presence or absence
of the Pgp-speciWc inhibitor zosuquidar (LY335979; 5 M;
[12]) in phenol red-free RPMI medium. After washing
thrice with ice-cold HBSS, the cells were lysed with Triton
X-100 (0.1%) in MilliQ water (Millipore, Bedford, MA,
USA). The ratio of intracellular rhodamine 123 concentra-
tions in the absence and presence of 5 M zosuquidar is
indicative for the eZux activity of Pgp.
Doxorubicin accumulation
LS180 cells (0.5 £ 106 c/well) were plated in a 24-well
plate. After a 48 h incubation with 0.1% DMSO or 10 M
rifampicin, cells were treated with 5 M doxorubicin for
90 min. Cells were washed thrice with ice-cold PBS, lysed
in 250 l MilliQ water, and homogenized by ultrasoniWca-
tion Labsonic P (Braun; cycle 0.2 min en Amplitude 60%).
Hundred microliters of the homogenate was processed for
HPLC analysis. Daunorubicin was used as an internal stan-
dard. The samples and standard solutions were prepared as
described by van Asperen et al. [13].
Doxorubicin HPLC analysis
Doxorubicin was quantiWed using a method as previously
described by DeGregorio et al. [14]. In brief, samples were
eluted isocratically with a mobile phase that consisted of
28% acetonitrile in 60 mM phosphoric acid. A Waters
Symmetry C18 3.5 M, 4.6 mm £ 100 mm reverse-phase
column was used. Fluorescence was detected using a
JASCO FP-920 Xuorometer (excitation: 455 nm; emission:
550 nm), Shimadzu LC10AT-VP pumps and a Shimadzu
SCL10A-VP controller. The Xow rate was set at 1.0 ml/
min. Doxorubicin and daunorubicin retention times were
2.38 and 5.01 min, respectively. A standard curve of doxo-
rubicin (0.08, 0.4, 2, 10 and 50 M) was prepared in milliQ
water.
Doxorubicin cytotoxicity assay
LS180 cells were plated (2 £ 104 cells/well; 96 well plates)
and treated with 10 M rifampicin or 0.1% DMSO. Follow-
ing 72 h incubation, cells were exposed to doxorubicin
(serially diluted 0–20 M; dilution factor 2). Cell viability
after 48 h doxorubicin exposure was assessed using a neu-
tral red assay [15].
Statistical analysis
One-way ANOVA with Bonferroni post hoc testing was
performed for statistical comparison of the obtained Pgp
reporter gene and activity results and considered statistically768 Cancer Chemother Pharmacol (2010) 66:765–771
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signiWcant when P < 0.05. All statistical calculations were
done in SPSS (v14, SPSS Inc. Chicago, IL, USA).
Results
Cell viability
Cell viability was assessed after 48 h treatment with diVer-
ent concentrations of the anticancer drugs. As shown in
Fig. 1, the anticancer drugs did not signiWcantly aVect the
LS180 cell viability at the concentrations used, while the
doxorubicin (10 M) did aVect cell viability.
PXR-mediated Pgp reporter activation by anticancer drugs
The ability of widely used anticancer drugs to induce the
expression of Pgp via activation of PXR was determined.
LS180 cells were transfected with a Pgp reporter construct
as well as a PXR expression plasmid. Treatment of the tran-
siently transfected LS180 cells with cyclophosphamide,
ifosfamide, docetaxel, paclitaxel, Xutamide, and tamoxifen
resulted in dose-dependent increases in Pgp reporter activ-
ity, while exposure to diVerent concentrations of carbo-
platin and etoposide did not increase PXR-mediated Pgp
reporter activity (Fig. 2). As a control, the same compounds
were tested in LS180 cells that were only transfected with
the Pgp reporter gene construct without co-transfection of a
PXR expression plasmid. In these cells, none of the com-
pounds was able to activate Pgp reporter activity (results
not shown).
Induction of Pgp protein expression
To evaluate whether Pgp reporter activation is predictive
for Pgp protein induction, the eVect of the anticancer drugs
on the protein expression levels of Pgp after 48 h treatment
in LS180 cells was determined. As shown in Fig. 3, all
compounds that were shown to activate PXR-mediated Pgp
reporter activity (vincristine, tamoxifen, vinblastine, doce-
Fig. 1 Cell viability after treatment with diVerent anticancer drugs.
LS180 cells were treated for 48 h with diVerent anticancer drugs. Cell
viability was assessed with a MTT-assay
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Fig. 2 PXR-mediated Pgp reporter gene activity following exposure
to anticancer drugs. LS180 cells were transfected with the pGL3-
MDR1 reporter construct, the nuclear receptor expression vectors
pCDG-hPXR, and the pRL-TK control vector. Cells were exposed to
anticancer drugs (range: 0.1–10 M; dilution factor 3) with the
exception ifosfamide and cyclophosphamide (0.3–100 M; dilution
factor 3). Rifampicin (10 M) was used as positive control. These re-
sults are the means (§SD) of three separate determinations and are
expressed as relative fold inductions compared to 0.1% DMSO
(*P < 0.05)
0
2
4
6
8
10
12
14
16
18
carboplatin etoposide vincristine tamoxifen vinblastine docetaxel cyclophosphamide flutamide ifosfamide paclitaxel rifampicin
R
e
l
a
t
i
v
e
 
P
g
p
 
r
e
p
o
r
t
e
r
 
a
c
t
i
v
i
t
y
*
*
*
*
*
* *
*
*
*
* *
*
* *Cancer Chemother Pharmacol (2010) 66:765–771 769
123
taxel, cyclophosphamide, Xutamide, ifosfamide and paclit-
axel) also induced Pgp protein levels in LS180 cells. In
accordance with the Pgp-reporter gene assay, both etopo-
side and carboplatin did not induce Pgp protein expression.
To further demonstrate that PXR plays an important role in
the upregulation of Pgp, PXR was knocked down in the
LS180 cells (knock down eYciency was 51% as was deter-
mined 48 h after siRNA transfection by Western blot
(results not shown)). The cells were subsequently treated
with the anticancer drugs. As shown in Fig. 3, Pgp protein
induction was signiWcantly lower in the PXR knockdown
LS180 cells after treatment with the anticancer drugs
compared to the control cells (LS180 cells transfected with
non-targeting siRNA). However, Pgp induction was not
completely abolished, most likely as a result of the knock-
down eYciency of 51%.
Rhodamine 123 accumulation assay
To assess whether PXR-mediated Pgp induction aVects
the accumulation of Pgp substrates, the transport activity
of Pgp was analyzed using a rhodamine 123 accumulation
assay. Following 48 h pretreatment with the anticancer
drugs, cells were exposed to rhodamine 123 in the absence
or presence of the Pgp-speciWc inhibitor zosuquidar
(LY335979; IC50 = 4nM) [16]. The ratio between the
intracellular Xuorescence of rhodamine 123 in the presence
and absence of zosuquidar is indicative for the Pgp trans-
port activity in the treated LS180 cells [11]. As shown in
Fig. 4, rhodamine 123 accumulation corresponds with Pgp
protein expression data; low cellular rhodamine 123 accu-
mulation was observed for paclitaxel, docetaxel and Xutam-
ide, which were shown to induce Pgp protein expression,
Fig. 3 Anticancer drugs aVect Pgp protein expression. Pgp protein
expression after exposure of the LS180 to the anticancer drugs as was
determined with immunoblotting using Pgp- and -actin-speciWc anti-
bodies. The Wgure shows a representative immunoblot of Pgp protein
expression in LS180 cells (both in control and PXR knock down cells)
following 48 h treatment with the indicated anticancer drugs
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while etoposide and carboplatin did not aVect rhodamine
123 accumulation. In contrast, the accumulation of rhoda-
mine 123 in the cells that were treated with the Vinca alka-
loids, cyclophosphamide, ifosfamide and tamoxifen did not
correspond with Pgp protein expression.
EVect of PXR activation on doxorubicin cytotoxicity
To study whether activation of PXR aVects the eYcacy of a
cytotoxic Pgp substrate, the eVect of PXR activation on the
cytotoxicity of doxorubicin in LS180 was assessed. There-
fore, prior to doxorubicin exposure, LS180 cells were pre-
treated with the prototypical PXR agonist 10 M rifampicin
or 0.1% DMSO (solvent) for 48 h. As shown in Fig. 5a, rif-
ampicin pretreatment aVects the intracellular accumulation
of doxorubicin. To determine whether reduced accumulation
of doxorubicin also aVects the eYcacy of this agent, rifampi-
cin- or solvent- pretreated cells were exposed to diVerent
doxorubicin concentrations (ranging from 0.3 to 20 M;
dilution factor 2). As shown in Fig. 5b, following doxorubi-
cin exposure cell viability was signiWcantly (P < 0.05)
higher in the rifampicin- pretreated cells (IC50 =2 . 5M)
compared to the solvent (0.1% DMSO) pretreated cells
(IC50 =1 . 5M). This indicates that PXR activation indeed
can reduce the activity of cytotoxic Pgp substrates as a result
of decreased intracellular accumulation.
Discussion
The development of MDR in response to anticancer treat-
ment is a major problem in the clinic. Since induction of
Pgp is one of the main mechanisms underlying acquired
MDR, we evaluated whether several widely used anticancer
drugs can induce Pgp expression via activation of PXR, a
nuclear receptor that is increasingly associated with
acquired MDR [9, 17].
Indeed, several anticancer drugs (vincristine, vinblas-
tine, cyclophosphamide, ifosfamide, docetaxel, Xutamide
and tamoxifen) were shown to increase Pgp reporter activ-
ity in cells co-transfected with a PXR expression plasmid.
In accordance, the same anticancer drugs induced Pgp pro-
tein expression in LS180 cells. However, when PXR was
knocked down in these cells treatment with the indicated
anticancer drugs did not result in Pgp protein induction.
Together these results indicate that PXR plays a substantial
role in anticancer drug-related Pgp induction.
Furthermore, since Pgp is a drug eZux transporter that is
involved in the extrusion of a wide variety of substrates
from the cell, the eVect of Pgp protein induction following
treatment with the indicated anticancer drugs on the intra-
cellular accumulation of Pgp substrates was evaluated.
Docetaxel, Xutamide, paclitaxel and the positive control rif-
ampicin that induced Pgp protein expression indeed
aVected the intracellular accumulation of the Pgp substrate
rhodamine 123. In addition, carboplatin and etoposide,
which had no eVect on Pgp protein expression, did not
aVect rhodamine 123 accumulation. However, tamoxifen
was shown to activate PXR-mediated Pgp protein induc-
tion, but did not aVect the accumulation of rhodamine 123.
This can be explained by the fact that tamoxifen is also a
known inhibitor of Pgp and thus prevents the Pgp-mediated
extrusion of rhodamine 123 [18]. The observed discrepancy
between the Pgp protein expression and Pgp functionality
Fig. 5 a Rifampicin pretreatment decreases doxorubicin accumula-
tion in LS180 cells. Doxorubicin accumulation was assessed in LS180
cells after 48 h pretreatment with rifampicin (10 M). These results are
derived from a representative experiment and data are the means
(§SD) from three separate determinations and is expressed as fold
decrease in doxorubicin accumulation compared to 0.1% DMSO
(**P < 0.01). b Rifampicin pretreatment reduces the cytotoxicity of
doxorubicin in LS180 cells. The eVect of 96 h rifampicin pretreatment
on the cytotoxicity of doxorubicin in LS180 was determined with a
neutral red assay. The results are presented as mean viabilities (§SD)
and are derived from four separate determinations (P <0 . 0 5 )
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after treatment with the Vinca alkaloids is diYcult to
explain and requires further investigation.
Since activation of PXR by anticancer drugs was shown
to aVect the accumulation of Pgp substrates, we further
assessed whether PXR activation could also attenuate the
cytotoxic eVects of doxorubicin, a known cytotoxic Pgp sub-
strate. However, to avoid potential pharmacodynamic inter-
actions between the selected anticancer drugs and
doxorubicin that could lead to increased cytotoxicity, we
chose to pretreat the cells with the prototypical PXR agonist
rifampicin. Indeed, pretreatment of LS180 cells with
rifampicin decreased the intracellular accumulation of the
cytotoxic Pgp substrate doxorubicin and additionally signiW-
cantly reduced the cytotoxic eYcacy of this agent. These
results indicate that activation of PXR-mediated Pgp induc-
tion by anticancer drugs can underlie the development of
acquired resistance. This is further supported by studies of
Chen et al. [9] and Gupta et al. [17], who have shown that
activation of PXR promotes the multidrug resistant pheno-
type of prostate and ovarian cancer cell lines, respectively.
Since Pgp is co-expressed with PXR in important barrier
tissues, such as the intestines and the liver, activation of
PXR-mediated Pgp induction could aVect the pharmacoki-
netic proWle of (oral) anticancer drugs. Indeed, drug-drug
interactions as a result of PXR-mediated Pgp induction
have been reported. For instance, intake of St. John’s wort,
which contains the PXR agonist hyperforin, by healthy vol-
unteers resulted in a 1.9-fold increase in the oral clearance
of the Pgp substrate fexofenadine [19], while rifampicin
pretreatment resulted in a 1.3- to 5.3-fold increase in the
oral clearance of fexofenadine [20]. In the same manner,
anticancer drugs that activate PXR might aVect their own
pharmacokinetics, but also that of other concomitantly
administered (anticancer) drugs.
In conclusion, several widely used anticancer drugs were
shown to activate PXR-mediated Pgp induction, and as a
result aVect the intracellular accumulation and cytotoxic
activity of Pgp substrates.
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